{
    "info": {
        "nct_id": "NCT06297226",
        "official_title": "A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)",
        "inclusion_criteria": "Inclusion Criteria\n\n* Documented diagnosis of multiple myeloma (MM) as per International Myeloma Working Group (IMWG) criteria.\n* Received at least 3 classes of MM treatment [including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb, and at least 3 prior lines of therapy (LOT).\n* Documented disease progression during or after their last anti-myeloma regimen as per IMWG 2016 criteria.\n* Participants must have measurable disease during screening.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\nExclusion Criteria\n\n* Active or history of central nervous system involvement with MM.\n* Active systemic fungal, bacterial, viral, or other infection despite appropriate anti-infective treatment at the time of leukapheresis.\n* Received any prior therapy directed at G protein-coupled receptor class C, group 5, member D (GPRC5D) or has received other prior treatment for MM without the required washout prior to leukapheresis.\n* Other protocol-defined Inclusion/Exclusion criteria apply.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have measurable disease during screening.",
            "criterions": [
                {
                    "exact_snippets": "measurable disease during screening",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "during screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Other protocol-defined Inclusion/Exclusion criteria apply.",
            "criterions": [
                {
                    "exact_snippets": "Other protocol-defined Inclusion/Exclusion criteria apply.",
                    "criterion": "other protocol-defined inclusion/exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received any prior therapy directed at G protein-coupled receptor class C, group 5, member D (GPRC5D) or has received other prior treatment for MM without the required washout prior to leukapheresis.",
            "criterions": [
                {
                    "exact_snippets": "Received any prior therapy directed at G protein-coupled receptor class C, group 5, member D (GPRC5D)",
                    "criterion": "prior therapy directed at GPRC5D",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has received other prior treatment for MM without the required washout prior to leukapheresis",
                    "criterion": "prior treatment for MM",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "washout period before leukapheresis",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active or history of central nervous system involvement with MM.",
            "criterions": [
                {
                    "exact_snippets": "Active or history of central nervous system involvement with MM.",
                    "criterion": "central nervous system involvement with MM",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "history"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Documented disease progression during or after their last anti-myeloma regimen as per IMWG 2016 criteria.",
            "criterions": [
                {
                    "exact_snippets": "Documented disease progression during or after their last anti-myeloma regimen as per IMWG 2016 criteria.",
                    "criterion": "disease progression",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "during or after their last anti-myeloma regimen"
                        },
                        {
                            "requirement_type": "definition_standard",
                            "expected_value": "IMWG 2016 criteria"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received at least 3 classes of MM treatment [including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb, and at least 3 prior lines of therapy (LOT).",
            "criterions": [
                {
                    "exact_snippets": "Received at least 3 classes of MM treatment",
                    "criterion": "classes of multiple myeloma (MM) treatment received",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "classes"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb",
                    "criterion": "types of MM treatment received",
                    "requirements": [
                        {
                            "requirement_type": "inclusion",
                            "expected_value": [
                                "immunomodulatory drug (IMiD)",
                                "proteasome inhibitor (PI)",
                                "anti CD38 mAb"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 3 prior lines of therapy (LOT)",
                    "criterion": "prior lines of therapy (LOT) received",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "lines of therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active systemic fungal, bacterial, viral, or other infection despite appropriate anti-infective treatment at the time of leukapheresis.",
            "criterions": [
                {
                    "exact_snippets": "Active systemic fungal, bacterial, viral, or other infection despite appropriate anti-infective treatment at the time of leukapheresis.",
                    "criterion": "systemic infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "fungal",
                                "bacterial",
                                "viral",
                                "other"
                            ]
                        },
                        {
                            "requirement_type": "response to anti-infective treatment",
                            "expected_value": "infection persists despite appropriate anti-infective treatment"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at the time of leukapheresis"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "Inclusion Criteria",
            "criterions": []
        },
        {
            "line": "* Documented diagnosis of multiple myeloma (MM) as per International Myeloma Working Group (IMWG) criteria.",
            "criterions": []
        },
        {
            "line": "Exclusion Criteria",
            "criterions": []
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}